Patents by Inventor Francois Gessier
Francois Gessier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312483Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: May 1, 2023Publication date: October 5, 2023Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Patent number: 11673868Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: October 22, 2021Date of Patent: June 13, 2023Assignee: Novartis AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20220041561Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammartory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancer e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Patent number: 11180460Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: September 16, 2019Date of Patent: November 23, 2021Assignee: Novartis AGInventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Publication number: 20200010426Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: September 16, 2019Publication date: January 9, 2020Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Patent number: 10457647Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: May 8, 2018Date of Patent: October 29, 2019Assignee: Novartis AGInventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Publication number: 20180251432Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: May 8, 2018Publication date: September 6, 2018Inventors: Daniela ANGST, Francois GESSIER, Anna VULPETTI
-
Publication number: 20180140602Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.Type: ApplicationFiled: April 7, 2016Publication date: May 24, 2018Inventors: Daniela Angst, John Byrd, Jason Dubovsky, Joseph A. Fraietta, Francois Gessier, Saar Gill, Amy Johnson, Carl H. June, Marcela Maus, Natarajan Muthusamy, David L. Porter, Marco Ruella, Anna Vulpetti, Mariusz Wasik
-
Patent number: 9512084Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: November 13, 2014Date of Patent: December 6, 2016Assignee: Novartis AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20160235746Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: April 21, 2016Publication date: August 18, 2016Applicant: NOVARTIS AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Patent number: 9051279Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: GrantFiled: February 27, 2013Date of Patent: June 9, 2015Assignee: Novartis AGInventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, Francois Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
-
Publication number: 20150152068Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: November 13, 2014Publication date: June 4, 2015Applicant: NOVARTIS AGInventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Publication number: 20130281473Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: ApplicationFiled: February 27, 2013Publication date: October 24, 2013Inventors: Joerg BERGHAUSEN, Nicole BUSCHMANN, Pascal FURET, Francois GESSIER, Joanna HERGOVICH LISZTWAN, Philipp HOLZER, Edgar JACOBY, Joerg KALLEN, Keiichi MASUYA, Carole PISSOT SOLDERMANN, Haixia REN, Stefan STUTZ
-
Patent number: 8497075Abstract: The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7,25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.Type: GrantFiled: July 12, 2009Date of Patent: July 30, 2013Assignees: Novartis AG, IRM LLC, Euroscreen SA, The Scripps Research InstituteInventors: Birgit Baumgarten, Francois Gessier, Andreas Katopodis, Richard Knochenmuss, Rocco Falchetto, Silvio Roggo, Andreas Sailer, Klaus Seuwen, Carsten Spanka, Juan Zhang, Sebastien Hannedouche, Sophie Noel, Marie-Odile Roy, Yu Chen, Charles Y. Cho, Wei Li, Weijun Shen
-
Patent number: 8440693Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: GrantFiled: December 20, 2010Date of Patent: May 14, 2013Assignee: Novartis AGInventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, François Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
-
Publication number: 20130012485Abstract: Compounds of the formula (I) are provided: wherein V, W, X, Y, Z, R3, R4, R5, R6, R7 and m are as defined in the specification; and pharmaceutically acceptable salts and prodrugs thereof. The compounds may be useful in the treatment or prevention of various diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.Type: ApplicationFiled: December 20, 2007Publication date: January 10, 2013Inventors: Daniel Kaspar Bäschlin, Richard Sedrani, Stefanie Flohr, Kenji Namoto, Nils Ostermann, Finton Sirockin, François Gessier, Garry Fenton, Mandy Christine Beswick, David Edward Clark, Bohdan Waszkowycz
-
Publication number: 20120149661Abstract: The invention relates to tetra-substituted heteroarylic compounds of the formula (I) wherein X1, X3 and X4 are independently C or N, Y is C—H, N—H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R?, R?, n and m are as defined herein. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.Type: ApplicationFiled: August 24, 2010Publication date: June 14, 2012Applicant: NOVARTIS AGInventors: Guido Bold, Pascal Furet, Francois Gessier, Joerg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Andrea Vaupel
-
Publication number: 20120077787Abstract: New compounds of the Formula (I): for the treatment of non-insulin-dependent diabetes mellitus.Type: ApplicationFiled: December 6, 2011Publication date: March 29, 2012Applicant: NOVARTIS AGInventors: Daniel Kaspar Baeschlin, Nils OSTERMANN, Francois GESSIER, Finton SIROCKIN, Kenji NAMOTO
-
Patent number: 8097617Abstract: New compounds of the Formula (I): for the treatment of non-insulin-dependent diabetes mellitus.Type: GrantFiled: March 29, 2007Date of Patent: January 17, 2012Assignee: Novartis AGInventors: Daniel Kaspar Baeschlin, Nils Ostermann, Francois Gessier, Finton Sirockin, Kenji Namoto
-
Publication number: 20110301157Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.Type: ApplicationFiled: August 17, 2011Publication date: December 8, 2011Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andrea Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
